medigraphic.com
ISSN 1561-2996 (Digital)
ISSN 0864-0289 (Impreso)

2019, Número 3

<< Anterior Siguiente >>

Rev Cubana Hematol Inmunol Hemoter 2019; 35 (3)


Importancia de las alteraciones genéticas del mieloma múltiple

Cuervo JF, Jaramillo P, López J

Idioma: Español
Referencias bibliográficas: 60
Paginas: 1-16
Archivo PDF: 379.26 Kb.


RESUMEN

Introducción: El mieloma múltiple (MM) es una enfermedad que va precedida por una fase previa conocida como gammapatía monoclonal de significado incierto (GMSI); en esta última existen varias anormalidades citogenéticas, que permiten la progresión a MM, entre estas encontramos reordenamientos primarios del gen de la cadena pesada de la inmunoglobina (IGH), además de células hiperdiploides. Desarrollo: Las alteraciones cromosómicas en el MM se pueden clasificar en dos grupos principales: las que involucran las translocaciones del locus IGH ubicado en el cromosoma 14q32 y cuyos principales reordenamientos se dan entre las regiones cromosómicas 11q13, 16q23, 4p16.3, 6p21 y, un segundo grupo caracterizado por los desequilibrios genómicos. Los pacientes con translocaciones de la IGH, muestran un pronóstico diferente en dependencia del tipo de reordenamiento cromosómico. La t(4;14)(p16;q32) y t(14;16)(q32;q23) se asocian a un mal pronóstico, mientras que los pacientes con t(11;14) (q13;q32) tiene un buen pronóstico de la enfermedad en ausencia de otras anormalidades genéticas. En el grupo con desequilibrio genómico se encuentran deleciones, amplificaciones, y células con números anormales de cromosomas (hiperdiploidas y no hiperdiploides); casi siempre asociadas a mal pronóstico ya que muchas de estas alteraciones involucran perdida de material genómico relacionado con el control de ciclo celular y progresión de la enfermedad, como son las deleciones de los cromosomas 1,13 y 17. Los pacientes con trisomías de los cromosomas impares 1, 3, 5, 7, 9, 11, 15, 19,21 suelen tener un mejor pronóstico y una tasa mayor de sobrevivencia.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. O’Donnell E, Cottini F, Raje N, Anderson K. Myeloma. In: Kaushansky K, Lichtman MA, Prchal JT, Levi MM, Press OW, Burns LJ, et al. Williams Hematology. 9th ed. New York:Mc Graw Hill; 2016. p. 1733–72.

  2. San Miguel J, Bladé J. Multiple myeloma. In: Hoffbrand V, Higgs DR, Keeling DM, Mehta AB. Postgraduate Haematology. 7th ed. Oxford: Wiley Blackwell; 2016. p. 577–98.

  3. McKenna RW, Kyle RA, Kuehl WM, Grogan TM, Harris NL, Coupland RW. Plasma cell neoplasms. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al; eds. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2016. p. 241–58.

  4. Gebregziabher M, Bernstein L, Wang Y, Cozen W. Risk patterns of multiple myeloma in Los Angeles County, 1972-1999 (United States). Cancer Causes Control. 2006;17(7):931–8.

  5. Brown LM, Linet MS, Greenberg RS, Silverman DT, Hayes RB, Swanson GM, et al. Multiple myeloma and family history of cáncer among blacks and whites in the U.S. Cancer. 1999.85:2385–90.

  6. Morgan GJ, Davies FE LM. Myeloma aetiology and epidemiology. Biomed Pharmacother. 2002;56:226–34.

  7. Corso A, Klersy C, Lazzarino M, Bernasconi C. Multiple myeloma in younger patients: the role of age as prognostic factor. Ann Hematol 1998;76:67-72.

  8. Khuder SA, Mutgi AB. Meta-analyses of multiple myeloma and farming. Am J Ind Med. 1997;32:510–16.

  9. Merhi M, Raynal H, Cahuzac E, Vinson F, Cravedi JP, Gamet-Payrastre L. Occupational exposure to pesticides and risk of hematopoietic cancers. Cancer Causes Control. 2007;18:1209–26.

  10. Raposo A, Peixoto D BM. Monoclonal gammapathy and rheumatic diseases. Acta Reum Port. 2014;39:12–8.

  11. Chng WJ, Bergsagel PL. The molecular biology of multiple myeloma. In: Provan D, Gribben JG, eds. Molecular Hematology. 3rd ed. Oxford: Wiley Blackwell ; 2011. p. 127–38.

  12. Owen J, Punt J, Stranford S, Jones P. KUBY. Inmunología. 7a ed. Mexico: Mc Graw Hill; 2013. p. 385–414.

  13. Chesi M, Bergsagel PL. Pathogenesis of Multiple Myeloma. In: Multiple Myeloma Diagnosis and Treatment. New York:Springer; 2014. p. 35–46.

  14. Seet CS, Crooks GM. Lymphopoiesis. In: Kaushansky K, Lichtman MA, Prchal JT, Levi MM, Press OW, Burns LJ, et al. Williams Hematology. 9th ed. New York:Mc Graw Hill; 2016. p. 1149–58.

  15. Calame KL. Plasma cells: Finding new light at the end of B cell development. Nat Immunol. 2001;2:1103.

  16. Landgren O, Kyle R a, Pfeiffer RM, Katzmann J a, Caporaso NE, Richard B, et al. consistently precedes multiple myeloma : a prospective study Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma : a prospective study. Blood. 2014;113(22):5412–7.

  17. Bianchi G, Munchi N. Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood,2015:125;3049-58.

  18. van de Donk NWCJ, Mutis T, Poddighe PJ, Lokhorst HM, Zweegman S. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Int J Lab Hematol. 2016;38:110–22.

  19. Pardoll DM. Molecular pathogenesis of multiple myeloma and its premalignant precursor. Nat Rev Cancer. 2012;12(10):252–64.

  20. Kuehl WM BP. Multiple myeloma: Evolving genetic events and host interactions. Nat Rev Cancer. 2002;2:175–187.

  21. 21.Hideshima T, Mitsiades C, Tonon G Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007;7:585.

  22. Jimenez C, Acevedo M, Corchete L, Castillo D, Ordoñez G, Sarasquete M, et al. A next-generation sequencing strategy for evaluating the most common genetic abnormalities in multiple myeloma. J Mol Diagn. 2017;19(1):99-106.

  23. Cagnetta A, Lovera D, Grasso R, Colombo N, Canepa L, Ballerini F, et al. Mechanisms and Clinical Applications of Genome Instability in Multiple Myeloma. Biomed Res.2015; 2015:1-8.

  24. Hu Y, Chen W, Chen S, Huang Z. Cytogenetic abnormality in patients with multiple myeloma analyzed by fluorescent in situ hybridization. Oncol Targets Ther. 2016;9:1145–9.

  25. Walker B, Wardell C, Johnson D, Kaiser M, Begun D, Dahir N, et al.Characterization of IGH locus breakpoints in multiple myeloma indicatesa subset of translocations appear to occur in pregerminal center B cells. Blood, 2013;121,(17):3413-9.

  26. Sawyer JR. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma. Cancer Genet. 2011;204(1):3–12.

  27. Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson K, et al.Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.Blood. 2016;127(24):2955-62

  28. Robillard N, Garand R, Moreau P, Pineau D. Brief report CD20 is associated with a small mature plasma cell morphology and t (11 ; 14) in multiple myeloma. Cell. 2003;102(3):1070–1.

  29. Gorczyca W. Plasma cell neoplasms. In: Gorczyca W. Atlas of Differential Diagnosis in Neoplastic Hematopathology. 3rd ed. New York: CRC Press; 2014. p. 359–81.

  30. Kalff A, Spencer A. The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies. Blood Cancer J. 2012;2(9):e89.

  31. Xie Z, Chng WJ. MMSET: Role and therapeutic opportunities in multiple myeloma. Biomed Res Int. 2014;2014:6–10.

  32. Moreau P, Attal M, Garban F, Hulin C, Facon T, Marit G, et al. Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials. Leukemia. 2007 Sep;21(9):2020-4.

  33. Chesi M, Bergsagel PL. Molecular pathogenesis of multiple myeloma: basic and clinical updates. Int J Hematol. 2013 Mar;97(3): 313–23.

  34. Jacobson S, Eggert J, Smith K, Rosenzweig T. Cytogenetics: Oncology nurses in advanced practice decipher del(13q14) and t(14:16). Clin J Oncol Nurs. 2012;16(6):221-5.

  35. Prideaux SM, Conway O’Brien E, Chevassut TJ. The genetic architecture of multiple myeloma. Adv Hematol. 2014;2014:864058.

  36. Yoshida S, Nakazawa N, Iida S, Hayami Y, Sato S, Wakita A, et al. Detection of MUM1/ IRF4-IgH fusion in multiple myeloma. Leukemia.1999 May; 13(11):1812–6.

  37. Heintel D, Zojer N, Schreder M, Strasser-Weippl K, Kainz B, Vesely M, et al. Expression of MUM1/IRF4 mRNA as a prognostic marker in patients with multiple myeloma. Leukemia. 2008;22(2):441–5.

  38. Besse L, Sedlarikova L, Greslikova H, Kupska R, Almasi M, Penka M, et al. Cytogenetics in multiple myeloma patients progressing into extramedullary disease. Eur J Haematol. 2016;97(1):93–100.

  39. Hideshima T, Cottini F, Nozawa Y, Seo H-S, Ohguchi H, Samur MK, et al. p53-Related Protein Kinase Confers Poor Prognosis and Represents a Novel Therapeutic Target in Multiple Myeloma. Blood. 2017 Mar 9;129(10):1308-19

  40. Herrero A, Rojas E, Misiewicz-Krzeminska I, Krzeminski P, Gutiérrez N. Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma. Int J Mol Sci. 2016;17(12):2003.

  41. Zang M, Zou D, Yu Z, Li F, Yi S, Ai X, et al. Detection of recurrent cytogenetic aberrations in multiple myeloma : A comparison between MLPA and iFISH.. Oncotarget. 2015 Oct;6(33):34276-87.

  42. Egan P, Drain S, Conway C, Bjourson AJ, Alexander HD. Towards stratified medicine in plasma cell myeloma. Int J Mol Sci. 2016;17(10):1–21.

  43. Liu H, Ding L, Shen Y, zhong F, Wang Q, Xu X. RBQ3 participates in multiple myeloma cell proliferation, adhesion and chemoresistance. Int J Biol Macromol. 2016;91:115–22.

  44. Mikulasova A, Wardell C, Murison A, Boyle E, Jackson G, Smetana J, et al.The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma. Haematologica. 2017;102(9):1617–25.

  45. Hanbali A, Hassanein M, Rasheed W, Aljurf M, Alsharif F. The Evolution of Prognostic Factors in Multiple Myeloma. Adv Hematol.2017;2017:1-11.

  46. Avet-Loiseau H, Attal M, Campion L, Caillot D, Hulin C, Marit G, et al. Long-term analysis of the ifm 99 trials for myeloma: Cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. J Clin Oncol. 2012;30(16):1949–52.

  47. Hebraud B, Leleu X, Lauwers-Cances V, Roussel M, Caillot D, Marit G, et al. Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients. Leukemia. 2013;28:675–9.

  48. Chapman M a, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, et al. Initial genome sequencing and analysis of multiple myeloma. Nature. 2013;471(7339):467–72.

  49. Leone PE, Walker BA, Jenner MW, Chiecchio L, Protheroe RKM, Johnson DC, et al. UKPMC Funders Group Deletions of CDKN2C in Multiple Myeloma : Biological and Clinical Implications.Clin Cancer Res 2009;14(19):6033–41.

  50. Chavan SS, He J, Tytarenko R, Deshpande S, Patel P, Bailey M, et al. Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker. Blood Cancer J. 2017;7(2):e535.

  51. Jian Y, Chen X, Zhou H, Zhu W, Liu N, Geng C, et al. Prognostic Impact of Cytogenetic Abnormalities in Multiple Myeloma: A Retrospective Analysis of 229 Patients. Medicine (Baltimore). 2016;95(19):e3521.

  52. Walker B a, Leone PE, Chiecchio L, Dickens NJ, Jenner MW, Boyd KD, et al. A compendium of myeloma associated chromosomal copy number abnormalities and their prognostic value. Blood. 2010;116(15):56–65.

  53. 53.Yu W, Guo R, Qu X, Qiu H, Li J, Zhang R, et al. The amplification of 1q21 is an adverse prognostic factor in patients with multiple myeloma in a Chinese population. Onco Targets Ther.2016 Jan 12;9:295-302

  54. Chakraborty R, Gertz MA. +1q: Amplifying the Bad Genes in Myeloma. Leuk Lymphoma. 2017 Aug;58(58):1771-73.

  55. Sawyer JR, Tian E, Heuck CJ, Epstein J, Johann DJ, Swanson CM, et al. Jumping translocations of 1q12 in multiple myeloma: A novel mechanism for deletion of 17p in cytogenetically defined high-risk disease. Blood. 2014 Apr. 123(16):2504–12.

  56. Demchenko Y, Roschke A, Chen WD, Asmann Y, Bergsagel PL, Kuehl WM. Frequent occurrence of large duplications at reciprocal genomic rearrangement breakpoints in multiple myeloma and other tumors. Nucleic Acids Res. 2016;44(17):8189–98.

  57. Robiou du Pont S, Cleynen A, Fontan C, Attal M, Munshi N, Corre J, et al. Genomics of Multiple Myeloma. J Clin Oncol. 2017;35(9):963-67. DOI: 10.1200/JCO.2016.70.6705ff.

  58. Chng WJ, Kumar S, VanWier S, Ahmann G, Price-Troska T, Henderson K, et al. Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res. 2007;67(7):2982–9.

  59. Pawlyn C, Melchor L, Murison A, Wardell CP, Brioli A, Boyle EM, et al. Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations. Blood. 2015;125(5):831–40.

  60. Van Wier S, Braggio E, Baker A, Ahmann G, Levy J, Carpten JD, et al. Hypodiploid multiple myeloma is characterized by more aggressive molecular markers than non-hyperdiploid multiple myeloma. Haematologica. 2013;98(10):1586–92.




2020     |     www.medigraphic.com